Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2020 May;145(5):e20192689.
doi: 10.1542/peds.2019-2689. Epub 2020 Apr 6.

Effect of State Immunization Information System Centralized Reminder and Recall on HPV Vaccination Rates

Peter Szilagyi  1 , Christina Albertin  2 , Dennis Gurfinkel  3 , Brenda Beaty  3 , Xinkai Zhou  4 , Sitaram Vangala  4 , John Rice  3   5 , Jonathan D Campbell  6 , Melanie D Whittington  6 , Rebecca Valderrama  7 , Abigail Breck  7 , Heather Roth  8 , Megan Meldrum  9 , Chi-Hong Tseng  4 , Cynthia Rand  2 , Sharon G Humiston  10 , Stanley Schaffer  2 , Allison Kempe  11   3
Affiliations
Randomized Controlled Trial

Effect of State Immunization Information System Centralized Reminder and Recall on HPV Vaccination Rates

Peter Szilagyi et al. Pediatrics. 2020 May.

Abstract

Background: Although autodialer centralized reminder and recall (C-R/R) from state immunization information systems (IISs) has been shown to raise childhood vaccination rates, its impact on human papillomavirus (HPV) vaccination rates is unclear.

Methods: In a 4-arm pragmatic randomized controlled trial across 2 states, we randomly selected practices representative of the specialty (pediatrics, family medicine, and health center) where children received care. Within each practice, patients 11 to 17.9 years old who had not completed their HPV vaccine series (NY: N = 30 616 in 123 practices; CO: N = 31 502 in 80 practices) were randomly assigned to receive 0, 1, 2, or 3 IIS C-R/R autodialer messages per vaccine dose. We assessed HPV vaccine receipt via the IIS, calculated intervention costs, and compared HPV vaccine series initiation and completion rates across study arms.

Results: In New York, HPV vaccine initiation rates ranged from 37.0% to 37.4%, and completion rates were between 29.1% and 30.1%, with no significant differences across study arms. In Colorado, HPV vaccine initiation rates ranged from 31.2% to 33.5% and were slightly higher for 1 reminder compared with none, but vaccine completion rates, ranging from 27.0% to 27.8%, were similar. On adjusted analyses in Colorado, vaccine initiation rates were slightly higher for 1 and 3 C-R/R messages (adjusted risk ratios 1.07 and 1.04, respectively); completion rates were slightly higher for 1 and 3 C-R/R messages (adjusted risk ratios 1.02 and 1.03, respectively).

Conclusions: IIS-based C-R/R for HPV vaccination did not improve HPV vaccination rates in New York and increased vaccination rates slightly in Colorado.

PubMed Disclaimer

Conflict of interest statement

POTENTIAL CONFLICT OF INTEREST: The authors have indicated they have no potential conflicts of interest to disclose.

Figures

FIGURE 1
FIGURE 1
Consolidated Standards of Reporting Trials diagram plus practice and patient eligibility criteria. HMO, health maintenance organization.
FIGURE 2
FIGURE 2
Example of an autodialer reminder script from New York (the script was read by computer-assisted human recording if an individual answered the autodialer call, and the voice sounded like a regular phone call).
FIGURE 3
FIGURE 3
Vaccine series initiation and completion rates in New York (A) and Colorado (B) at the end of the study.
See this image and copyright information in PMC

Comment in

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Jemal A, Simard EP, Dorell C, et al. . Annual report to the nation on the status of cancer, 1975–2009, featuring the burden and trends in human papillomavirus (HPV)-associated cancers and HPV vaccination coverage levels. J Natl Cancer Inst. 2013;105(3):175–201 - PMC - PubMed
    1. Dunne EF, Unger ER, Sternberg M, et al. . Prevalence of HPV infection among females in the United States. JAMA. 2007;297(8):813–819 - PubMed
    1. Zandberg DP, Bhargava R, Badin S, Cullen KJ. The role of human papillomavirus in nongenital cancers. CA Cancer J Clin. 2013;63(1):57–81 - PubMed
    1. Centers for Disease Control and Prevention (CDC) Human papillomavirus-associated cancers - United States, 2004-2008. MMWR Morb Mortal Wkly Rep. 2012;61:258–261 - PubMed
    1. Van Dyne EA, Henley SJ, Saraiya M, Thomas CC, Markowitz LE, Benard VB. Trends in human papillomavirus-associated cancers - United States, 1999–2015. MMWR Morb Mortal Wkly Rep. 2018;67(33):918–924 - PMC - PubMed

Publication types

Substances